Vaccine HPV

The cervical cancer,is the most common cancer affecting women in developing countries. The most common oncogenic HPV genotypes are 16 and 18, causing approximately 70% of all cervical cancers. HPV is highly transmissible, it is transmitted mainly through sexual activity. HPV vaccine was recently approved in several countries following the determination that has an acceptable benefit between the risks, the vaccine prevented 100% of moderate and severe precancerous cervical lesions in women without prior infection with this type, in clinical trials. Vaccines are prepared from particles non-infectious, know as free virus  these particles are produced by DNA recombinant technology and adds an adjuvant. The vaccine is three doses,with three doses induced high levels of antibodies in virtually all vaccinated individuals.  In women who do not have evidence of past or current infection with HPV, the vaccine offers protection from about 90% against persistent HPV for five years. This vaccine not generated adverse events, in general only redness of the puncture site, this generates more interest in the population. Is necesary Vaccination at an early age, before women are exposed to HPV  this would have the greatest impact  epidemiological in the cervical cancer. Since HPV vaccines do not eliminate the risk of cervical cancer, the PAP test cervical screening will still be required to minimize cancer incidence. High prices of vaccines against HPV, so this  vaccines is not  accessible for the populations; the funding mechanism is essential for that vaccines arrive the most needy populations.

the human papillomavirus vaccine

Aims: This topic is very important for our career because the Genital human papillomavirus (VPH /HPV) is one of the most common sexually transmitted infections worldwide.
Purpose: This work explais the efficiency of vaccine HPV and  how to use it.
Methods: Revicion of different papers about the HPV vaccine and its effectiveness in preventing virus.
Results: The vaccine virus-like particles without DNA produced by recombinant technology and combined with an adjuvant. This is given in three doses, offering protection from about 90% during five years aprox.
Conclusions: This vaccine is a good tool for reducing the number of  HPV infections but is costly what make it less accessible to the population.